Aptamer Group plc (LSE:APTA) has announced the signing of a significant new contract worth up to £617,000 with a top-five global pharmaceutical company — marking the third collaboration between the two firms. The agreement underscores the growing commercial momentum of Aptamer’s Optimer® technology platform, which will be used to develop binders for three key drug targets. Retaining full intellectual property rights allows Aptamer to pursue future licensing opportunities, further expanding potential revenue streams. With contract value visibility up 46% year-on-year, the company is strengthening its position for sustainable revenue growth and reinforcing its strong base of repeat business with major pharmaceutical partners.
Despite encouraging commercial progress, Aptamer Group continues to face financial pressures, including high debt levels and ongoing unprofitability. Technical indicators remain weak, but strategic partnerships and a rising number of corporate milestones offer positive signs for long-term recovery and growth.
More about Aptamer Group plc
Aptamer Group plc is a biotechnology company specializing in the development of next-generation synthetic binders, known as Optimer® binders. These innovative molecules serve as alternatives to antibodies, providing high stability, consistency, and cost advantages for use in therapeutics, diagnostics, and research applications. Operating in the global antibody-alternative market, valued at around US$210 billion, Aptamer collaborates with leading pharmaceutical and biotechnology companies. Founded in 2008 and listed on the AIM market of the London Stock Exchange in 2021, the company is headquartered in York, UK.
Leave a Reply